Meet the NeuroArbor team

Scientific commitment and patient-centric clinical expertise are the pillars of our work. Our team collaborates with leading universities and experts in the field of liver and metabolic disorders, neurology and psychiatry.

Our scientists and clinicians have worked in top medical institutions, including, among others, Harvard University, Cornell University, the University of Texas, Johns Hopkins University,The University of Padova, The University of Milano, The Swiss Italian University (USI), Memorial Sloan Kettering Cancer Center, Mount Sinai Hospital, Massachusetts General Hospital.

Paolo Manfredi

Chief Scientific Officer and Chief Executive Officer

Paolo Manfredi is a neurologist and co-founder of Medeor Inc. a joint venture with Cornell Center for Technology Enterprise & Commercialization (CCTEC). Medeor then merged to form Relmada Therapeutics, a publicly traded biotechnology company. Dr. Manfredi is a co-inventor of several pharmaceutical patents currently under development. REL-P11 (MR psilocybin) has successfully completed a Phase 1 study in overweight-obese subjects and in normal BMI subjects and is preparing for Phase 2 studies. REL-1017 (esmethadone), a well tolerated and safe oral, once-daily NMDA receptor antagonist is currently in Phase 3 for the adjunctive treatment of major depressive disorder by Levomecor Inc.

Marco Pappagallo

Chief Medical Officer and Head of Safety

Marco Pappagallo is a Neurologist and Clinical Professor of Anesthesiology at Albert Einstein College of Medicine, New York. Marco is an internationally renowned researcher and lecturer with over 100 publications and a seasoned inventor of pharmaceuticals. Marco has conducted (PI) clinical trials sponsored by NIH, Glaxo, Roche, and Pfizer and has held CMO positions in several biotechnology companies, including Relmada Therapeutics. Marco is a co-inventor on the psilocybin platform, which includes REL-P11, a Phase 2-ready molecule.

Marco Massini is an investor, board director, and operating CFO with deep experience in financial strategy, M&A, and value creation for private-equity-backed companies. He has supported the growth and financial governance of 15+ portfolio companies across consumer, industrial, and technology sectors. His expertise spans enterprise valuation, budgeting and forecasting, cash-flow optimization, debt and equity structuring, turn-around support and board-level reporting, with a strong focus on cross-border operations between the U.S. and Europe. Marco holds an MBA from Columbia Business School and a B.S. in Mechanical Engineering from the University of Parma.

Marco Massini

Chief Financial Officer

Board of Directors

Andrea Alimonti, MD

Andrea Alimonti is Director of the Institute of Oncology Research. He is Professor of Oncology at ETH Zurich and the Università della Svizzera italiana, and Professor of Pharmacology at the University of Padua. He previously worked at Memorial Sloan Kettering Cancer Center and Harvard Medical School. Andrea Alimonti is an expert in cellular senescence and senescence-based therapeutic strategies for cancer and aging.

Giorgio Andreacci

Giorgio Andreacci is an entrepreneur and executive with international experience in technology, innovation, and corporate strategy. He co-founded Infinity Technology Solutions S.p.A. and later founded Demetra Technologies Srl, where he serves as President and Board Director. He also holds several institutional roles, including Chairman of the Executive Board of Dixet Group, Supervisory Board Member of SIIT, and Board Member of Genova Smart City Association.

Paolo Manfredi, MD

Paolo Manfredi is a neurologist and co-founder of Medeor Inc., created in partnership with the Cornell Center for Technology Enterprise & Commercialization. Medeor later merged into Relmada Therapeutics, where Dr. Manfredi contributed to the development of several pharmaceutical patents. Among them are REL-1017 (esmethadone), currently in Phase 3 for major depressive disorder, and REL-P11 (MR psilocybin), now preparing for Phase 2 studies.

Advisors

Sara De Martin

Head of Preclinical Metabolism

Stefano Comai

Head of Preclinical CNS

Andrea Mattarei

Head of Chemistry, Manufacturing, and Controls and Derivatives

Gianfranco Pasut

Head of PEG program

Franco Folli

Head of Clinical Translation

Gaia Rizzo

Scientific Coordinator

Chiara Sanguineti

Head of Administration